What exactly is testosterone approved for?
Testosterone products are approved for men whose low testosterone has a medical cause. The FDA’s testosterone information page says they are approved only for men who lack or have low testosterone in conjunction with an associated medical condition, giving testicular failure and problems of the hypothalamus or pituitary as examples.
Doctors call that classical hypogonadism. The Depo-Testosterone label frames its indication the same way: replacement therapy for primary hypogonadism (a testicular cause) or hypogonadotropic hypogonadism (a pituitary or hypothalamic cause).
| Type of low T | Typical cause | Label status |
|---|---|---|
| Primary hypogonadism | Testicular damage, surgery, genetic conditions such as Klinefelter syndrome | Approved indication |
| Secondary hypogonadism | Pituitary or hypothalamic disease, tumors, injury | Approved indication |
| Age-related low T | Gradual decline with no single identifiable cause | Off-label; limitation of use under revision since June 2026 |
Our pages on primary and secondary hypogonadism explain how each is identified.
What did the 2015 label change do?
It drew a line around aging. After a 2014 safety communication about reported strokes, heart attacks and deaths, the FDA issued a March 2015 communication that, in the words of its 2025 labeling announcement, informed of required labeling changes and urged caution when using testosterone for low testosterone.
The result was a “limitation of use” printed on every label. The Depo-Testosterone label still carries the standard wording: safety and efficacy in men with “age-related hypogonadism,” also called late-onset hypogonadism, have not been established. That sentence is what people mean when they say TRT is not FDA-approved for aging.
Why can a clinician still treat age-related low T?
Because label status and good medical practice are not the same thing. The FDA’s page on off-label use explains that health care providers may generally use an approved drug for an unapproved purpose when they judge it medically appropriate, even though the FDA has not reviewed that use.
Guidelines fill the gap. The Endocrine Society suggests against routinely treating every man over 65 with a low number, but it suggests offering therapy on an individualized basis to men with symptoms and consistently low morning levels, after an explicit discussion of risks and benefits. Its July 2026 statement goes further on definitions: the diagnosis is the same at any age, labels such as “age-related” and “functional” are hard to pin down, and symptoms alone are never enough.
So the practical test is not your birthday. It is whether symptoms and repeated early-morning results agree, and whether fixable causes have been ruled out. Our answer on what testosterone level qualifies for TRT shows the numbers guidelines use.
What did the 2025 update change?
On February 28, 2025, the FDA required class-wide changes to every testosterone label. It added the results of the TRAVERSE heart safety trial, removed the boxed warning language about increased cardiovascular risk, and added a warning about increased blood pressure. It deliberately kept the age-related limitation of use at that time.
That combination mattered for older men, since heart risk had been the main worry behind the 2015 caution. Our article on the 2025 testosterone label changes covers each part in detail.
What changed in June 2026?
The FDA’s testosterone information page reports that in June 2026 the agency requested further label updates. Two stand out: removing the limitation of use about age-related hypogonadism, and revising the wording on prostate cancer and benign prostate enlargement. The FDA says the request followed a review of new data and reanalysis of existing evidence, including TRAVERSE.
Two cautions keep this in proportion. First, the approved indication itself is still described as low testosterone with an associated medical condition; the request removes a warning sentence rather than adding aging as a new use. Second, labels change product by product. As of early October 2026, the Depo-Testosterone label on DailyMed, last revised in September 2025, still showed the older limitation.
How Ultimate Male approaches low T in older men
At our San Gabriel and Downey clinics, age does not decide anything on its own. Morning labs are drawn on site, and a PA-C or MD reviews two results, your symptoms, your medicines and your health history, including the reversible causes the Endocrine Society asks clinicians to check first.
If treatment makes sense, you hear plainly whether your situation fits the label or the guideline-supported off-label path, and what monitoring follows. Men over 65 can read our answer on starting TRT after 65, and anyone weighing it can learn more about testosterone therapy before booking the free call.
